<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40019">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01680523</url>
  </required_header>
  <id_info>
    <org_study_id>KGOG 1029</org_study_id>
    <nct_id>NCT01680523</nct_id>
  </id_info>
  <brief_title>Radical Hysterectomy Followed by Tailored Adjuvant Therapy Versus Primary Chemoradiation Therapy in Bulky Early-stage Cervical Cancer (KGOG 1029)</brief_title>
  <official_title>A Randomized Controlled Trial Comparing Radical Hysterectomy Plus Tailored Adjuvant Therapy Versus Primary Chemoradiation Therapy in Bulky Early-stage Cervical Cancer (KGOG 1029)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <authority>Korea: Asan Medical Center Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare 5-year overall survival between patients who undergo radical hysterectomy
      followed by tailored adjuvant therapy and patients who receive primary chemoradiation
      therapy in FIGO stage IB2 and IIA2 cervical cancer
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>5-year overall survival</measure>
    <time_frame>5 year after treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>5-year progression-free survival</measure>
    <time_frame>5 years after treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pattern of disease recurrence</measure>
    <time_frame>within 5 years afer treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related toxicity</measure>
    <time_frame>within 5 years after treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Treatment related toxicity will be evaluated using CTCAE v3.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>within 1 year after treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">409</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>RH group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radical hysterectomy followed by tailored adjuvant therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CCRT group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Primary concurrent chemoradiation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radical hysterectomy</intervention_name>
    <description>Piver-Rutledge type III hysterectomy New classification type C2 hysterectomy Open, vaginal, laparoscopic assisted, laparoscopic, robotic radical hysterectomy are all allowed</description>
    <arm_group_label>RH group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Tailored adjuvant therapy</intervention_name>
    <description>After radical hysterectomy, intermediate risk group according to GOG protocol 92 criteria will receive adjuvant radiation therapy. High risk group will receive adjuvant chemoradiation therapy with weekly cisplatin (40mg/m2, IV for 6 cycles). Extended filed radiation therapy is allowed in case of common iliac lymph node or para-aortic lymph node metastasis. Intracavitary brachytherapy and nodal or parametrial boost is not allowed.</description>
    <arm_group_label>RH group</arm_group_label>
    <other_name>Adjuvant radiation therapy</other_name>
    <other_name>Adjuvant chemoradiation therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Primary chemoradiation therapy</intervention_name>
    <description>Patient will receive primary radiation therapy including external pelvic irradiation, intracavitary brachytherapy, and parametrial or nodal boost. Extended filed radiation therapy is allowed in case of common iliac lymph node enlargement. Patients will receive concurrent weekly cisplatin (cisplatin 40mg/m2 for 6 cycles) during external radiation therapy.</description>
    <arm_group_label>CCRT group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously untreated, histologically confirmed cervical cancer

          -  FIGO stage IB2 and IIA2 disease

          -  One of following histologic types

               1. Squamous cell carcinoma

               2. Adenocarcinoma

               3. Adenosquamous carcinoma

          -  Gynecologic Oncology Group performance status: 0-2

          -  Adequate organ function

               1. Bone marrow: WBC &gt; 3000/mm3, ANC ≥ 1,000/mm3, Platelet ≥ 100*103/mm3, Hemoglobin
                  ≥ 10g/dL

               2. Kidney: Creatine &lt; 1.25 * upper normal limit

               3. Liver: AST, ANT &lt; 3 * upper normal limit, Total bilirubin &lt; 1.5 mg/mm3

          -  Patient who have Singed an approved informed consent

        Exclusion Criteria:

          -  Patients with cervical cancer who have received any previous radiation or
             chemotherapy

          -  Neuroendocrine carcinoma of uterine cervix

          -  Occult cervical cancer which was found after simple hysterectomy

          -  Para-aortic nodal involvement (&gt; 10 mm short axis diameter on pretreatment imaging
             study)

          -  History of other invasive malignancies, with the exception of non-melanoma skin
             cancer, in situ melanoma and thyroid cancer, who had (or have) no evidence of the
             other cancer present within the last 5 years

          -  Serious illness or medical condition that precludes the safe administration of the
             trial treatment including, but not limited to, ongoing or active infection,
             symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia,
             or psychiatric illness/social situations that would limit compliance with study
             requirements

          -  Prior diagnosis of Crohn's disease or ulcerative colitis

          -  Neurologic or psychiatric disease

          -  Patients who are pregnant or lactating
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joo-Hyun Nam, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joo-Hyun Nam, M.D., Ph.D.</last_name>
    <phone>82-2-3010-3633</phone>
    <email>jhnam@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joo-Hyun Nam, M.D., Ph.D.</last_name>
      <phone>82-2-3010-3633</phone>
      <email>jhnam@amc.seoul.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 8, 2012</lastchanged_date>
  <firstreceived_date>September 4, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Joo-Hyun Nam</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>cervical cancer</keyword>
  <keyword>bulky early-stage</keyword>
  <keyword>locally advanced</keyword>
  <keyword>radical hysterectomy</keyword>
  <keyword>concurrent chemoradiation therapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
